VXRT News and Press, Vaxart Inc. From 03/20/19

Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the closing of its previously announced registered direct offering of 1,200,000 shares of its common stock at a price of $2.50 p...

Gainers:  Estre Ambiental (NASDAQ: ESTR ) +81% . Motif Bio plc (NASDAQ: MTFB ) +71% . Nevro (NYSE: NVRO ) +33% . Electrameccanica Vehicles (NASDAQ: SOLO ) +32% . Dragon Victory International (NASDAQ: LYL ) +21% . Fibrocell Science (NASDAQ: FCSC ) +18% . Amira Nature Foods (NYSE:...

Soleno Therapeutics (NASDAQ: SLNO ) -10% . More news on: Soleno Therapeutics, Inc., Tencent Music Entertainment Group, Cellectar Biosciences, Inc., Stocks on the move, Read more ...

CORAL GABLES, FL/ ACCESSWIRE / March 19, 2019 / In the last few months, the healthcare stock market has responded favorably to the fact that the healthcare industry is one of the fastest changing sectors in the global marketplace. Naturally, over time, the global population has increased i...

Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary oral vaccine platform, today announced that it has entered into definitive agreements with certain institutional investors for the purchase...

Gainers:  Vaxart (NASDAQ: VXRT ) +108% . Sorrento Therapeutics (NASDAQ: SRNE ) +34% . Conformis (NASDAQ: CFMS ) +23% . Blucora (NASDAQ: BCOR ) +20% . StoneCo (NASDAQ: STNE ) +19% . Realm Therapeutics ( RLM ) +19% . Iterum Therapeutics (NASDAQ: ITRM ) +18% . Altimmune (NASDAQ: A...

Altimmune (NASDAQ: ALT ) +44%  on positive NasoVAX data . More news on: Altimmune, Inc., Vaxart, Inc., Cellectar Biosciences, Inc., Stocks on the move, Read more ...

- First Dosing with Norovirus GII.4 Oral Tablet Vaccine Scheduled for Week of March 18 - Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced the initiation of a Phase 1b ...

The Wait On The ResVax Preliminary Data Is Nearly Over A couple of months ago I wrote an article on Novavax ( NVAX ) detailing the upcoming catalysts set to hit in early 2019 stating the stock would remain in the $1.50-$2.50 price range as anticipation builds on the release of 2 main preli...

Vaxart (NASDAQ: VXRT ): Q4 GAAP EPS of -$0.69. Revenue of $1.77M (+132.9% Y/Y) Press Release More news on: Vaxart, Inc., Earnings news and commentary, Healthcare stocks news, ,